adh-1
Small moleculeexperimental
Clinical trial activity
6 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00265057)
Timeline
Indications
Mechanism of action
- Cadherin-2INHIBITOR
CDH2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@H]1CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O- Mol. weight
- 570.7 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3818130 ↗
Also known as
- adh -1
- adh -1
- adh-1
- adh-1
- adh-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01825603 | Phase 1 | Apr 1, 2013 | Fennec Pharma, National Cancer Institute (NCI), University of Nebraska |
| NCT00421811 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2007 | Duke University, Fennec Pharma |
| NCT00390676 | Phase 1 | Nov 1, 2006 | Fennec Pharma, US Oncology |
| NCT00264433 | Phase 2 | Dec 12, 2005 | Fennec Pharma |
| NCT00225550 | Phase 1/Phase 2 (Phase 2) | Sep 22, 2005 | Fennec Pharma |
| NCT00265057 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2005 | Fennec Pharma |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fennec Pharma | For profit | 6 | 5 | 2 | 2005 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2013 |
| University of Nebraska | Academic/Hospital | 1 | 1 | 1 | 2013 |
| US Oncology | For profit | 1 | 0 | 1 | 2006 |
5 organizations
Page 1 / 1